Amsbio offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies. Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for treatment of children and adolescents with B cell acute lymphoblastic leukemia (ALL).
Amsbio Business Development Manager – Dr Maja Petkovic commented “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This success inspired new research that demonstrated CAR-T cell…
San Diego, CA – September 15, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. The addition of the new GS knockout cell lines will further enhance speed, scalability, and flexibility for biopharma customers.Named AbZelectPRO™-KO and AbZelectPRO™-KO+, the new GS knockout platforms are available as a…
LONDON, UK and BOSTON, MA - September 18, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alltrna and is pleased to announce the placement of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO).Alltrna, a Flagship Pioneering company, is unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease.With nearly two decades of drug development experience, Dr. Hava has led multidisciplinary teams that…
Victoria House, a newly restored Grade II listed building in London’s Bloomsbury Square, officially opened its doors yesterday (16 September) as a state-of-the-art life sciences hub.
Developed by Oxford Properties and Pioneer Group, converted by CW Architects and delivered by contractor Wates, the 300,000 sq ft facility redefines the capital’s science and technology landscape. The building offers a unique combination of lab-enabled, fully fitted and incubator laboratory space and serviced offices within highly technical, tailored infrastructure – supporting the full lifecycle of life sciences…
Learnings From Pop and Rap Stars for Genesis There is an old saying, popularised more recently by Pitbull and Christina Aguilera, that goes, ‘Ask for money, get advice; ask for advice, get money twice.’ This has perhaps never been truer than in the life sciences sector over recent times when advice has been far more freely given than investment. This is the motivation for the new Company Showcase stream introduced at Genesis this year, which will include fifty pitches from growing companies on their dealmaking journey.Striving to be EfficientFor several years now the desire to be…
Cambridge, UK – 17 September 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.
This international trial has recruited 41 patients at clinical centres in the UK, France, Italy, and Spain. Initial results are expected in the first half of 2026.
MELODY-1 is a Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who…
A new research report, commissioned by Pioneer Group and The Crown Estate, has found that investing £15bn in UK university spinouts over the next 10 years could leverage a further £27bn of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, and boosting UK science on the global stage.
Authored by Henham Strategy, the report, titled: ‘Bridging the Capital Gap for UK Research Commercialisation,’ outlines the investment needed to translate the UK’s scientific excellence into global impact.
The findings suggest that replicating the model of Oxford…
LONDON, UK, and MILAN, Italy, September 16, 2025 – Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Valerio Ferri as Chief Executive Officer (CEO) at ExoLab Italia.ExoLab Italia is a biotech company producing plant-based exosomes for the cosmetics, nutraceutical, and pharmaceutical markets.With extensive experience in the nutraceutical and pharmaceutical sectors, Valerio Ferri joins ExoLab Italia after holding senior roles in leading companies such as Biofarma Group,…
Amsbio offers a wide selection of over 325,000 pre-characterized chemical compounds to support your drug screening applications for discovery and development.
From individual inhibitors, agonists and natural products to ready-to-screen compound libraries, these cost-effective, high-quality reagents are perfect for both academic and industrial research.
Whether you are studying apoptosis, autophagy, cell cycle regulation, immunology, or signaling cascades our portfolio of over 20,000 small molecule inhibitors and agonists offer excellent membrane permeability…
The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.
Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals.
Radiopharmaceuticals are a growing class of medicines that contain radioactive forms of chemical elements (called radioisotopes) that effectively diagnose and treat cancers. They provide a rapidly advancing approach to the future of medical research and…